For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best ...

Discover Veru Inc.'s Q3 2025 earnings insights, including Phase III enobosarm trial updates, FDA feedback, and nondilutive funding plans for ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

A large-scale cohort study has found that GLP-1s, including Ozempic and Wegovy, may be associated with a modestly increased risk of developing diabetic retinopathy. The research, published Aug. 11 in ...

As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, ...

Discover how GLP-1 medications and the MAHA movement are driving protein consumption and creating new opportunities for ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

The Today’s Dietitian 13th annual Spring Symposium will be returning to vibrant Orlando, Florida, in 2026. Secure your spot today by registering at www.todaysdietitian.com/ss26. We are excited to see ...

A company that has Donald Trump Jr. on its board debuted a new service to help pharmaceutical companies launch direct sales ...

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...